{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036518","form_type":"8-K","ticker":"PLSH","cik":"0001552189","company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","filed_at":"2022-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.116707+00:00","generated_at":"2026-06-20T22:50:26.591672+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Panacea repays $1.11M convertible note; CEO credit line raised to $5M","bullets":["Repaid $1,110,306.85 on Dec 21, 2022 to retire a 10% OID senior convertible note issued Nov 2021.","Original note had $1.1M principal, 10% discount, and warrants for 785,715 shares at $1.40/share.","Funding came from CEO line of credit, which was amended to increase borrowing capacity to $5M.","Note maturity was Nov 16, 2022; repayment satisfied all obligations under the Purchase Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036518","json":"https://secwatch.observer/filing/0001493152-22-036518.json","markdown":"https://secwatch.observer/filing/0001493152-22-036518.md","text":"https://secwatch.observer/filing/0001493152-22-036518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/0001493152-22-036518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T22:50:26.591672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3eed17ad0022e409814f41cf588fb7ddfbe2e68a","claim":"PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Securities Purchase Agreement with an institutional investor valued at $1,000,000 (effective 2021-11-16).","evidence_excerpt":"On November 16, 2021, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) pursuant to which the Company sold a 10% original issue discount senior convertible promissory note in the principal amount of $1,100,000 (the “Note”) and five-year warrants to purchase 785,715 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) pursuant to the terms and conditions of the SPA for a total purchase price of $1,000,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1552189/000149315222036518/0001493152-22-036518-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$1,000,000"},{"label":"Effective","value":"2021-11-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}